Measurement of conatumumab-induced apoptotic activity in tumors by fine needle aspirate sampling

Cytometry Part A

Volumn 77, Issue 9, 2010, Pages 849-860

  Zoog, Stephen J ^a   Ma, Connie Y ^a   Kaplan Lefko, Paula J ^a   Hawkins, Jennifer M ^a   Moriguchi, Jodi ^a   Zhou, Lei ^a   Pan, Yang ^b   Hsu, Cheng Pang ^a   Friberg, Greg ^a   Herbst, Roy ^c   Hill, John ^a   Juan, Gloria ^a  

^a AMGEN INC   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Conatumumab; Fine needle aspirates; apoptosis; caspase 3

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CONATUMUMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL; APOPTOSIS; ARTICLE; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG SCREENING; ENZYMOLOGY; FEMALE; FLOW CYTOMETRY; HUMAN; LUNG TUMOR; METHODOLOGY; MOUSE; NEEDLE BIOPSY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOPSY, FINE-NEEDLE; CASPASE 3; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; MICE; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956457949     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.20940     Document Type: Article

References (42)

1. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10: 66-75.
2. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-113.
3. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, GrayCL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control ofTRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-821.
4. Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC, McLaughlin MM, Srinivasula SM, Livi GP, Marshall LA, Alnemri ES, Williams WV, Doyle ML. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the high-estaffinityreceptor. J Biol Chem 2000;275:23319- 23325.
5. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, Rauch CT. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL. EMBO J 1997;16:5386-5397.
6. Peter ME, Krammer PH. The CD95 (APO-1/Fas) DISC and beyond. Cell Death Differ 2003;10:26-35.
7. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/ TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000;12:611-620.
8. Lavrik I, Krueger A, Schmitz I, Baumann S, Weyd H, Krammer PH, Kirchhoff S. The active caspase-8 heterotetramer is formed at the CD95 DISC. Cell Death Differ 2003;10:144-145.
9. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH, Walczak H. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor. Immunity 2000;12:599-609.
10. Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochon-drialrelease of Smac/DIABLO. Genes Dev 2002; 16:33-45.
11. Suliman A, Lam A, Datta R, Srivastava RK. Intracellular mechanisms of TRAIL: Apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 2001;20:2122-2133.
12. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008;26:3621-3630.
13. Pollack IF, Erff M, Ashkenazi A. Direct stimulation of apoptotic signaling by soluble Apo2L/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing ofgliomacells. Clin Cancer Res 2001;7:1362-1369.
14. Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, Ross S, Deforge L, Koep- pen H, Sagolla M, Compaan D, Lowman H, Hymowitz S, Ashkenazi A. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomaband theproapoptotic receptorDRCell Death Differ 2008;15:751-761.
15. Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H, Ashkenazi A, Kim KJ. Isotype-dependent inhibition of tumor growth in vivo by mono- clonalantibodies to death receptor. J Immunol 2001;166:4891-4898.
16. Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, Carbone A, Albert V, Younes A. Activity of selective fully human agonistic antibodies to the TRAILdeathreceptorsTRAIL-R1 andTRAIL-R2inprimaryandculturedlymphoma cells: Induction of apoptosis and enhancement of doxorubicin- and bortezomib-inducedcelldeath. BrJ Haematol 2005;130:501-510.
17. Guo Y, Chen C, Zheng Y, Zhang J, Tao X, Liu S, Zheng D, Liu Y. A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independenT cell death. J Biol Chem 2005;280:41940-41952.
18. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004;4:333-339.
19. Kaplan-Lefko PJ, Graves JD, Zoog SJ, Pan Y, Wall J, Branstetter DG, Moriguchi J, Coxon A, Huard JN, Xu R, Peach ML, Juan G, Kaufman S, Chen Q, Bianchi A, Kor- dich JJ, Ma M, Foltz IN, Gliniak BC. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. CancerBiol Ther 2010;9:616-629.
20. LoRusso P, Hong D, Heath E, Kurzrock R, Wang D, Hsu M, Goyal L, Wiezorek J, Storgard C, Herbst R. First-in-human studyofAMG 655, a pro-apoptotic TRAIL re- ceptor-2 agonist, in adult patients with advanced solid tumors. J Clin Oncol ASCO Annu Meeting Proc I 2007;25(18S):3534.
21. Boeddinghaus I, Johnson SR. Serial biopsies/fine-needle aspirates and their assessment. Methods MolMed 2006;120:29-41.
22. Saleh H, Masood S. Value of ancillary studies in fine-needle aspiration biopsy. Diagn Cytopathol 1995;13:310-315.
23. Brotherick I, Shenton BK, Lennard TW. Are fine-needle breast aspirates representative of the underlying solid tumour? A comparison of receptor levels, ploidy and the influence of cytokeratin gates. Br J Cancer 1995;72:732-737.
24. Nizzoli R, Bozzetti C, Naldi N, Guazzi A, Gabrielli M, Michiara M, Camisa R, Barilli A, Cocconi G. Comparison of the results of immunocytochemical assays for biologic variables on preoperative fine-needle aspirates and on surgical specimens ofprimary breast carcinomas. Cancer 2000;90:61-66.
25. Kulesza P, Eltoum IA. Endoscopic ultrasound-guided fine-needle aspiration: Sampling, pitfalls, and qualitymanagement. Clin Gastroenterol Hepatol2007;5: 1248-1254.
26. Schwock J, Ho JC, Luther E, Hedley DW, Geddie WR. Measurement of signaling pathway activities in solid tumor fine-needle biopsies by slide-based cytometry. Diagn Mol Pathol2007;16:130-140.
27. Zabaglo L, Ormerod MG, Dowsett M. Measurement of markers for breast cancer in a model systemusing laser scanning cytometry. Cytometry2000;41:166- 171.
28. Zabaglo L, Ormerod MG, Dowsett M. Measurement of proliferation marker Ki67 in breast tumour FNAs using laser scanning cytometry in comparison to conventional immunocytochemistry. Cytometry B Clin Cytom 2003;56B:55-61.
29. Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F. Cytometry in cell necrobiology: Analysis of apoptosis and accidental cell death (necrosis). Cytometry 1997;27:1-20.
30. Assersohn L, Salter J, Powles TJ, A'Hern R, Makris A, Gregory RK, Chang J, Dowsett M. Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Res Treat 2003;82:113-123.
31. Gerstner AO, Laffers W, Tarnok A. Clinical applications of slide-based cytometry-an update. J Biophotonics 2009;2:463-469.
32. Nizzoli R, Bozzetti C, Crafa P, Naldi N, Guazzi A, Di Blasio B, Camisa R, Cascinu S. Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas. Diagn Cytopathol 2003;28:142-146.
33. Ostrowski ML, Pindur J, Laucirica R, Chakraborty S, Ramzy I. Proliferative activity in invasive breast carcinoma: A comprehensive comparison of MIB-1 immunocyto- chemical staining in aspiration biopsies to image analytic, flow cytometric and histo- logic parameters. Acta Cytol 2001;45:965-972.
34. Verstovsek G, Chakraborty S, Ramzy I, Jorgensen JL. Large B-cell lymphomas: Fine- needle aspiration plays an important role in initial diagnosis ofcases which are falsely negative by flow cytometry. Diagn Cytopathol 2002;27:282-285.
35. Yoder M, Zimmerman RL, Bibbo M. Two-color immunostaining of liver fine needle aspiration biopsies with CD34 and carcinoembryonic antigen. Potential utilization in the diagnosis of primary hepatocellular carcinoma vs. metastatic tumor. Anal Quant CytolHistol 2004;26:61-64.
36. Zimmerman RL, Logani S, Baloch Z. Evaluation of the CD34 and CD10 immunostains using a two-color staining protocol in liver fine-needle aspiration biopsies. Diagn Cytopathol 2005;32:88-91.
37. Baker M. In biomarkers we trust? Nat Biotechnol 2005;23:297-304.
38. Bakhtiar R. Biomarkers in drug discovery and development. J Pharmacol Toxicol Methods 2008;57:85-91.
39. Rifai N, Gerszten RE. Biomarker discoveryand validation. Clin Chem 2006;52:1635-1637.
40. Biven K, Erdal H, Hagg M, Ueno T, Zhou R, Lynch M, Rowley B, Wood J, Zhang C, Toi M, Shoshan MC, Linder S. A novel assay for discovery and characterization of pro- apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis 2003;8:263-268.
41. Stomper PC, Budnick RM, Stewart CC. Use ofspecimen mammography-guided FNA (fine-needle aspirates) for flow cytometric multiple marker analysis and immunophe- notyping in breastcancer. Cytometry2000;42:165-173.
42. Fan AC, Deb-Basu D, Orban MW, Gotlib JR, Natkunam Y, O'Neill R, Padua RA, Xu L, Taketa D, Shirer AE, Beer S, Yee AX, Voehringer DW, Felsher DW. Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Nat Med 2009;15:566-571.